Evidence map›Paper›PMID 35046133›Full record

ArticleJournal of psychiatry & neuroscience : JPN

Multidimensional predictors of negative symptoms in antipsychotic-naive first-episode psychosis.

Alba Toll, Laura Blanco-Hinojo, Daniel Bergé, Xavier Duran, Irene Canosa, Teresa Legido, Federico Marmol, Víctor Pérez-Solà, Emilio Fernández-Egea, Anna Mané

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of psychiatry & neuroscience : JPN. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alba TollFrom the Institut de Neuropsiquiatria i Adiccions (INAD), Parc de Salut Mar, Barcelona, Spain (Toll, Bergé, Canosa, Legido, Pérez-Solà, Mané); the Fundació Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Toll, Bergé, Duran, Canosa, Legido, Pérez-Solà, Mané); the Centro de Investigación Biomédica en Red, Área de Salud Mental (CIBERSAM), Spain (Toll, Blanco-Hinojo, Bergé, Canosa, Pérez-Solà, Mané); the Department of Psychiatry and Forensic Medicine, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Toll); the MRI Research Unit, Department of Radiology, Parc de Salut Mar, Barcelona, Spain (Blanco-Hinojo); the Pharmacology Unit, Department of Clinical Fundamentals, Faculty of Medicine, Barcelona University, Barcelona, Spain (Marmol); and the Department of Psychiatry and Behavioral and Clinical Neuroscience Institute, University of Cambridge, United Kingdom (Fernández-Egea).
Laura Blanco-HinojoFrom the Institut de Neuropsiquiatria i Adiccions (INAD), Parc de Salut Mar, Barcelona, Spain (Toll, Bergé, Canosa, Legido, Pérez-Solà, Mané); the Fundació Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Toll, Bergé, Duran, Canosa, Legido, Pérez-Solà, Mané); the Centro de Investigación Biomédica en Red, Área de Salud Mental (CIBERSAM), Spain (Toll, Blanco-Hinojo, Bergé, Canosa, Pérez-Solà, Mané); the Department of Psychiatry and Forensic Medicine, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Toll); the MRI Research Unit, Department of Radiology, Parc de Salut Mar, Barcelona, Spain (Blanco-Hinojo); the Pharmacology Unit, Department of Clinical Fundamentals, Faculty of Medicine, Barcelona University, Barcelona, Spain (Marmol); and the Department of Psychiatry and Behavioral and Clinical Neuroscience Institute, University of Cambridge, United Kingdom (Fernández-Egea) laura.blanco02@gmail.com.
Daniel BergéFrom the Institut de Neuropsiquiatria i Adiccions (INAD), Parc de Salut Mar, Barcelona, Spain (Toll, Bergé, Canosa, Legido, Pérez-Solà, Mané); the Fundació Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Toll, Bergé, Duran, Canosa, Legido, Pérez-Solà, Mané); the Centro de Investigación Biomédica en Red, Área de Salud Mental (CIBERSAM), Spain (Toll, Blanco-Hinojo, Bergé, Canosa, Pérez-Solà, Mané); the Department of Psychiatry and Forensic Medicine, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Toll); the MRI Research Unit, Department of Radiology, Parc de Salut Mar, Barcelona, Spain (Blanco-Hinojo); the Pharmacology Unit, Department of Clinical Fundamentals, Faculty of Medicine, Barcelona University, Barcelona, Spain (Marmol); and the Department of Psychiatry and Behavioral and Clinical Neuroscience Institute, University of Cambridge, United Kingdom (Fernández-Egea).
Xavier DuranFrom the Institut de Neuropsiquiatria i Adiccions (INAD), Parc de Salut Mar, Barcelona, Spain (Toll, Bergé, Canosa, Legido, Pérez-Solà, Mané); the Fundació Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Toll, Bergé, Duran, Canosa, Legido, Pérez-Solà, Mané); the Centro de Investigación Biomédica en Red, Área de Salud Mental (CIBERSAM), Spain (Toll, Blanco-Hinojo, Bergé, Canosa, Pérez-Solà, Mané); the Department of Psychiatry and Forensic Medicine, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Toll); the MRI Research Unit, Department of Radiology, Parc de Salut Mar, Barcelona, Spain (Blanco-Hinojo); the Pharmacology Unit, Department of Clinical Fundamentals, Faculty of Medicine, Barcelona University, Barcelona, Spain (Marmol); and the Department of Psychiatry and Behavioral and Clinical Neuroscience Institute, University of Cambridge, United Kingdom (Fernández-Egea).
Irene CanosaFrom the Institut de Neuropsiquiatria i Adiccions (INAD), Parc de Salut Mar, Barcelona, Spain (Toll, Bergé, Canosa, Legido, Pérez-Solà, Mané); the Fundació Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Toll, Bergé, Duran, Canosa, Legido, Pérez-Solà, Mané); the Centro de Investigación Biomédica en Red, Área de Salud Mental (CIBERSAM), Spain (Toll, Blanco-Hinojo, Bergé, Canosa, Pérez-Solà, Mané); the Department of Psychiatry and Forensic Medicine, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Toll); the MRI Research Unit, Department of Radiology, Parc de Salut Mar, Barcelona, Spain (Blanco-Hinojo); the Pharmacology Unit, Department of Clinical Fundamentals, Faculty of Medicine, Barcelona University, Barcelona, Spain (Marmol); and the Department of Psychiatry and Behavioral and Clinical Neuroscience Institute, University of Cambridge, United Kingdom (Fernández-Egea).
Teresa LegidoFrom the Institut de Neuropsiquiatria i Adiccions (INAD), Parc de Salut Mar, Barcelona, Spain (Toll, Bergé, Canosa, Legido, Pérez-Solà, Mané); the Fundació Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Toll, Bergé, Duran, Canosa, Legido, Pérez-Solà, Mané); the Centro de Investigación Biomédica en Red, Área de Salud Mental (CIBERSAM), Spain (Toll, Blanco-Hinojo, Bergé, Canosa, Pérez-Solà, Mané); the Department of Psychiatry and Forensic Medicine, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Toll); the MRI Research Unit, Department of Radiology, Parc de Salut Mar, Barcelona, Spain (Blanco-Hinojo); the Pharmacology Unit, Department of Clinical Fundamentals, Faculty of Medicine, Barcelona University, Barcelona, Spain (Marmol); and the Department of Psychiatry and Behavioral and Clinical Neuroscience Institute, University of Cambridge, United Kingdom (Fernández-Egea).
Federico MarmolFrom the Institut de Neuropsiquiatria i Adiccions (INAD), Parc de Salut Mar, Barcelona, Spain (Toll, Bergé, Canosa, Legido, Pérez-Solà, Mané); the Fundació Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Toll, Bergé, Duran, Canosa, Legido, Pérez-Solà, Mané); the Centro de Investigación Biomédica en Red, Área de Salud Mental (CIBERSAM), Spain (Toll, Blanco-Hinojo, Bergé, Canosa, Pérez-Solà, Mané); the Department of Psychiatry and Forensic Medicine, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Toll); the MRI Research Unit, Department of Radiology, Parc de Salut Mar, Barcelona, Spain (Blanco-Hinojo); the Pharmacology Unit, Department of Clinical Fundamentals, Faculty of Medicine, Barcelona University, Barcelona, Spain (Marmol); and the Department of Psychiatry and Behavioral and Clinical Neuroscience Institute, University of Cambridge, United Kingdom (Fernández-Egea).
Víctor Pérez-SolàFrom the Institut de Neuropsiquiatria i Adiccions (INAD), Parc de Salut Mar, Barcelona, Spain (Toll, Bergé, Canosa, Legido, Pérez-Solà, Mané); the Fundació Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Toll, Bergé, Duran, Canosa, Legido, Pérez-Solà, Mané); the Centro de Investigación Biomédica en Red, Área de Salud Mental (CIBERSAM), Spain (Toll, Blanco-Hinojo, Bergé, Canosa, Pérez-Solà, Mané); the Department of Psychiatry and Forensic Medicine, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Toll); the MRI Research Unit, Department of Radiology, Parc de Salut Mar, Barcelona, Spain (Blanco-Hinojo); the Pharmacology Unit, Department of Clinical Fundamentals, Faculty of Medicine, Barcelona University, Barcelona, Spain (Marmol); and the Department of Psychiatry and Behavioral and Clinical Neuroscience Institute, University of Cambridge, United Kingdom (Fernández-Egea).
Emilio Fernández-EgeaFrom the Institut de Neuropsiquiatria i Adiccions (INAD), Parc de Salut Mar, Barcelona, Spain (Toll, Bergé, Canosa, Legido, Pérez-Solà, Mané); the Fundació Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Toll, Bergé, Duran, Canosa, Legido, Pérez-Solà, Mané); the Centro de Investigación Biomédica en Red, Área de Salud Mental (CIBERSAM), Spain (Toll, Blanco-Hinojo, Bergé, Canosa, Pérez-Solà, Mané); the Department of Psychiatry and Forensic Medicine, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Toll); the MRI Research Unit, Department of Radiology, Parc de Salut Mar, Barcelona, Spain (Blanco-Hinojo); the Pharmacology Unit, Department of Clinical Fundamentals, Faculty of Medicine, Barcelona University, Barcelona, Spain (Marmol); and the Department of Psychiatry and Behavioral and Clinical Neuroscience Institute, University of Cambridge, United Kingdom (Fernández-Egea).
Anna ManéFrom the Institut de Neuropsiquiatria i Adiccions (INAD), Parc de Salut Mar, Barcelona, Spain (Toll, Bergé, Canosa, Legido, Pérez-Solà, Mané); the Fundació Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Toll, Bergé, Duran, Canosa, Legido, Pérez-Solà, Mané); the Centro de Investigación Biomédica en Red, Área de Salud Mental (CIBERSAM), Spain (Toll, Blanco-Hinojo, Bergé, Canosa, Pérez-Solà, Mané); the Department of Psychiatry and Forensic Medicine, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Toll); the MRI Research Unit, Department of Radiology, Parc de Salut Mar, Barcelona, Spain (Blanco-Hinojo); the Pharmacology Unit, Department of Clinical Fundamentals, Faculty of Medicine, Barcelona University, Barcelona, Spain (Marmol); and the Department of Psychiatry and Behavioral and Clinical Neuroscience Institute, University of Cambridge, United Kingdom (Fernández-Egea).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite a large body of schizophrenia research, we still have no reliable predictors to guide treatment from illness onset. The present study aimed to identify baseline clinical or neurobiological factors - including peripheral brain-derived neurotrophic factor (BDNF) levels and amygdala or hippocampal relative volumes - that could predict negative symptomatology and persistent negative symptoms in first-episode psychosis after 1 year of follow-up.

methodsWe recruited 50 drug-naive patients with first-episode psychosis and 50 age- and sex-matched healthy controls to study brain volumes. We performed univariate and multiple and logistic regression analyses to determine the association between baseline clinical and neurobiological variables, score on the PANSS negative subscale and persistent negative symptoms after 1 year of follow-up.

resultsLow baseline serum BDNF levels ( LIMITATIONS: We were unable to assess negative symptoms and their dimensions with next-generation scales, which were not available when the study was initiated.

conclusionThis study shows that a set of variables at baseline, including low BDNF levels, smaller left amygdala relative volume and score on the PANSS negative subscale are significant predictors of outcomes in first-episode psychosis. These findings might offer an initial step for tailoring treatments in first-episode psychosis.

Indexed as

Antipsychotic AgentsPsychotic DisordersSchizophreniaBrain-Derived Neurotrophic FactorHippocampusHumansAntipsychotic AgentsBrain-Derived Neurotrophic Factor

Identifiers

PMID35046133
PMCPMC8789336

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.